芪胶升白胶囊联合化疗对肿瘤患者白细胞减少及化疗效果的临床观察

Therapeutic efficacy and bone marrow protection of Qijiao Shengbai Capsule for cancer patients with chemotherapy

目的观察芪胶升白胶囊联合化疗对肿瘤患者白细胞及化疗效果的疗效。方法 83例肿瘤化疗患者随机分为联合组(化疗联合口服芪胶升白胶囊)42例和对照组(化疗)41例。联合组患者口服芪胶升白胶囊2 g/次,3次/d,服用6天为1个疗程,对照组仅予常规化疗,5个疗程后观察检测白细胞水平(WBS)、血红蛋白(Hb)和血小板(Plt)检测值及身体指标,并观察不良反应。结果 5个疗程后,联合组WBC、Hb、Plt均较治疗前升高,而对照组较治疗前降低,其明显低于联合组(P<0.05);通过临床症状观察,联合组缓解率和未进展率分别为59.5%和73.8%,而对照组的缓解率和未进展率分别为41.5%和58.5%,两组比较差异有统计学意义(P<0.05)。结论芪胶升白胶囊对肿瘤患者骨髓功能有保护作用,并能减轻不良反应,加强治疗效果。

Objective To evaluate the therapeutic efficacy and bone marrow protection effect of Qijiao Shengbai Capsule with chemotherapy in cancer patients. Methods Eighty-three cancer patients were randomly assigned into two groups： 42 patients under＇went chemotherapy combined with Chinese herb medicine Qijiao Shengbai Capsule 2.0 g tid （experimental group） and 41 patients received chemotherapy only （control group ）. The WBS, Hb and Plt were measured before treatment and after 5 treatment courses, and adverse reactions were observed. Results After 5 treatment courses, the WBS, Hb and Ph levels in experimental group were elevated, and were significantly higher than those in control group （ P 〈 0. 05）. The response rate （RR） and disease control rate （DCR） in experimental group were 59. 5% and 73. 8% , and those in control group were 41. 5% and 58. 5% （P 〈 0. 05 ）. Conclusion Qijiao Shengbai Capsule can effectively promote the efficacy of chemotherapy and protect the bone marrow function during cancer chemotherapy.